There is an association between the concentration of circulating LDL cholesterol (LDL-c) and the risk of cardiovascular disease.  There is an unmet need for more effective and tolerable<unk>  for the reduction of LDL-c.  Ongoing studies are evaluating novel lipid-lowering therapeutic strategies, including anti-sense oligonucleotides (ASOs) to apolipoprotein B (apo B), proprotein convertase subtilisin/kexin type 9 (PCSK9), microsomal triglyceride transfer protein (MTP), thyromimetics, squalene synthase, adenosine triphosphate-citrate lyase, AMP-activated protein kinase, and sterol regulatory element binding proteins.
Low density lipoprotein future or investigational therapies
High density lipoprotein future or investigational therapies
High density lipoprotein medical therapy
Low density lipoprotein medical therapy
High cholesterol secondary prevention
High cholesterol primary prevention
Metabolic syndrome dietary therapy
High density lipoprotein epidemiology and demographics